Nothing Special   »   [go: up one dir, main page]

DK3233054T3 - Formuleringer af en PI3K/MTOR-hæmmer til intravenøs administration - Google Patents

Formuleringer af en PI3K/MTOR-hæmmer til intravenøs administration Download PDF

Info

Publication number
DK3233054T3
DK3233054T3 DK15813578.0T DK15813578T DK3233054T3 DK 3233054 T3 DK3233054 T3 DK 3233054T3 DK 15813578 T DK15813578 T DK 15813578T DK 3233054 T3 DK3233054 T3 DK 3233054T3
Authority
DK
Denmark
Prior art keywords
pi3k
formulations
intravenous administration
mtor inhibitor
mtor
Prior art date
Application number
DK15813578.0T
Other languages
English (en)
Inventor
Kevin Richard Back
Michael Cram
Aidan James Harper
W James Huang
Jonathan Richard Lillis
Timothy Michael Lukas
Sumit Luthra
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK3233054T3 publication Critical patent/DK3233054T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK15813578.0T 2014-12-17 2015-12-10 Formuleringer af en PI3K/MTOR-hæmmer til intravenøs administration DK3233054T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462093060P 2014-12-17 2014-12-17
US201562250633P 2015-11-04 2015-11-04
PCT/IB2015/059515 WO2016097949A1 (en) 2014-12-17 2015-12-10 Formulations of a pi3k/mtor-inhibitor for intravenous administration

Publications (1)

Publication Number Publication Date
DK3233054T3 true DK3233054T3 (da) 2021-08-02

Family

ID=54937330

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15813578.0T DK3233054T3 (da) 2014-12-17 2015-12-10 Formuleringer af en PI3K/MTOR-hæmmer til intravenøs administration

Country Status (25)

Country Link
US (2) US10172942B2 (da)
EP (1) EP3233054B1 (da)
JP (1) JP6420753B2 (da)
KR (1) KR102016822B1 (da)
CN (1) CN107205923B (da)
AU (1) AU2015365497B2 (da)
CA (1) CA2915199C (da)
CY (1) CY1124527T1 (da)
DK (1) DK3233054T3 (da)
ES (1) ES2881214T3 (da)
HR (1) HRP20211446T1 (da)
HU (1) HUE055928T2 (da)
IL (1) IL252158B (da)
LT (1) LT3233054T (da)
MX (1) MX2017008072A (da)
NZ (1) NZ731518A (da)
PL (1) PL3233054T3 (da)
PT (1) PT3233054T (da)
RS (1) RS62337B1 (da)
RU (1) RU2672875C1 (da)
SG (1) SG11201703826TA (da)
SI (1) SI3233054T1 (da)
TW (1) TWI660729B (da)
WO (1) WO2016097949A1 (da)
ZA (1) ZA201703764B (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3672571T (lt) * 2017-08-25 2021-12-10 Pfizer Inc. Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidą
AU2019283550B2 (en) * 2018-06-07 2022-06-16 Pfizer Inc. Aqueous formulation comprising 1-(4-{(4-(dimethylamino)piperidin-1-yl)carbonyl}phenyl)-3-(4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl)urea
JP2024529430A (ja) 2021-07-26 2024-08-06 セルキュイティー インコーポレイテッド がんの処置における使用のための1-(4-{[4-(ジメチルアミノ)ピペリジン-1-イル]カルボニル}フェニル)-3-[4-(4,6-ジモルホリン-4-イル-1,3,5-トリアジン-2-イル)フェニル]尿素(ゲダトリシブ)およびその組合せ

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
CN101257903A (zh) * 2005-05-27 2008-09-03 拜耳医药保健股份公司 用于癌症治疗的包括二芳基脲化合物和PI3、AKT激酶或mTOR抑制剂(雷帕霉素类)的组合治疗
US20080234262A1 (en) * 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
DE202008001253U1 (de) * 2008-01-28 2008-04-10 Mirror Image Ag Bildanzeigegerät
PT2294072T (pt) 2008-05-23 2017-05-29 Wyeth Llc Compostos de triazina como inibidores de p13 quinase e mtor
RU2509081C2 (ru) * 2008-05-30 2014-03-10 Дженентек, Инк. Пуриновые соединения, ингибирующие рi3к, и способы применения
WO2010096619A1 (en) * 2009-02-23 2010-08-26 Wyeth Llc Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
US9757432B2 (en) * 2012-11-14 2017-09-12 Ohio State Innovation Foundation Materials and methods useful for treating glioblastorna
BR112015022047A8 (pt) * 2013-03-14 2019-12-10 Abraxis Bioscience Llc uso de uma composição compreendendo nanopartículas contendo um fármaco da família limo e uma albumina
GEP20207083B (en) * 2014-03-14 2020-04-10 Pfizer Therapeutic nanoparticles comprising therapeutic agent and methods of making and using same

Also Published As

Publication number Publication date
BR112017010841A2 (pt) 2017-12-26
JP6420753B2 (ja) 2018-11-07
LT3233054T (lt) 2021-07-26
CA2915199A1 (en) 2016-06-17
CY1124527T1 (el) 2022-07-22
KR20170082638A (ko) 2017-07-14
ZA201703764B (en) 2020-11-25
HUE055928T2 (hu) 2022-01-28
ES2881214T3 (es) 2021-11-29
TWI660729B (zh) 2019-06-01
AU2015365497A1 (en) 2017-06-01
SG11201703826TA (en) 2017-07-28
EP3233054B1 (en) 2021-06-30
TW201632188A (zh) 2016-09-16
US20190105390A1 (en) 2019-04-11
CN107205923B (zh) 2021-03-05
CN107205923A (zh) 2017-09-26
HRP20211446T1 (hr) 2021-12-24
EP3233054A1 (en) 2017-10-25
NZ731518A (en) 2019-03-29
SI3233054T1 (sl) 2021-11-30
AU2015365497B2 (en) 2020-07-02
MX2017008072A (es) 2017-09-28
JP2016113461A (ja) 2016-06-23
KR102016822B1 (ko) 2019-08-30
IL252158A0 (en) 2017-07-31
CA2915199C (en) 2018-11-06
RU2672875C1 (ru) 2018-11-20
IL252158B (en) 2021-01-31
PL3233054T3 (pl) 2021-12-20
PT3233054T (pt) 2021-08-02
US20170360935A1 (en) 2017-12-21
WO2016097949A1 (en) 2016-06-23
US10660959B2 (en) 2020-05-26
RS62337B1 (sr) 2021-10-29
US10172942B2 (en) 2019-01-08

Similar Documents

Publication Publication Date Title
DK3797742T3 (da) Indretning til suprakoroidal indgivelse af terapeutisk middel
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
DK3110475T3 (da) Indretning til administration af et fluidprodukt
DK3139986T3 (da) System til administration af terapeutisk gas
DK3722274T3 (da) 2-perfluorbutylpentan til oftalmisk indgivelse
DK3119762T3 (da) Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft
DK2968071T3 (da) Enhed til oral levering af terapeutiske forbindelser
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3831833T3 (da) Fremgangsmåder til fremstillingen af en pi3k-inhibitor
DK3372584T5 (da) Fremgangsmåde til fremstillingen af en diarylthiohydantoin-forbindelse
DK3511319T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3116491T3 (da) Farmaceutiske sammensætninger af terapeutisk aktive forbindelser
DK3204398T3 (da) Fremgangsmåder til fraseparering af gemcitabin-phosphat diastereoisomerer
DK3378482T5 (da) Formulering til administration af antitumorlægemiddel
DK3068776T3 (da) Inhibitorer af replikation af influenzavira
DK3237045T3 (da) Indretning til indgivelse af lægemidler
DK3287133T3 (da) Proton-bindende polymerer til oral indgivelse
DK3512857T3 (da) Spiro-bicykliske inhibitorer af menin-mll-interaktion
HUE049057T2 (hu) Proton-kötõ polimerek orális beadásra
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK2948134T3 (da) Sammensætninger til transdermal indgivelse af mtor-inhibitorer
DK3149000T3 (da) Krystallinsk tosylatsalt af en pi3k-delta-selektiv inhibitor til anvendelse i farmaceutiske formuleringer
IL262738B (en) Intravenous infusion set
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
DK2981258T3 (da) Farmaceutiske formuleringer til subkutan indgivelse af furosemid